The landmark procedure was performed on a critically ill 61-year-old patient named Bijayentimala Devi from Manipur diagnosed ...

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and con ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

He mentored medical students at UC, held numerous board positions, and remains the top fundraiser for Blood Cancer United's Ohio River Valley Region.He was the face of Peter's Pals at Light the Night.

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

Zanzalintinib and atezolizumab improved overall survival in metastatic colorectal cancer compared to regorafenib, with a median OS of 10.9 vs 9.4 months. The combination showed progression-free ...

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

Penn State Health held a bell-ringing ceremony on Monday, Oct. 20, for a new cancer center that will open in Enola. The Penn ...

The European Society for Medical Oncology (ESMO) released today the ESMO Guidance on the Use of Large Language Models in ...